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fold.8,9 Since early on in the HIV epidemic, multiple cases 
of HIV-ALS have been described.10-16 HIV-ALS can cause a 
clinical presentation compatible with sporadic ALS (sALS).
[15] HIV-ALS tends to occur at younger age, with a more 
severe and progressive phenotype.7,10-15 The occurrence of 
HIV-ALS is not related to the duration or stage of the HIV 
infection.14
SSA accounts for over 70% of the global HIV epidemic. 
There has been no literature on HIV-ALS from SSA apart 
from a recent study from South Africa, a country with higher 
socioeconomic level and a multi-ethnic patient population.7 
An association of HIV and MND was suggested in a large 
cohort of MND patients from Northern Tanzania.4 One 
patient from the same series with HIV-ALS is described in 
this report. He was treated with ART and clinically stabi-
lised over 10 years. 
In patients with HIV-ALS a response to ART has been 
described in previous case reports.7,10-15 The diagnostic con-
sideration of HIV-ALS is important since treatment with 
ART can affect the course of the disease. 
Case report 
In June 2007, a 41 year old male was admitted to Kili-
manjaro Christian Medical Centre (KCMC), a tertiary re-
ferral centre in Northern Tanzania. He had a nine month 
history of a nasal speech, progressive difficulty chewing and 
swallowing for seven months and difficulty walking for six 
months. Around the same time he had developed a seizure 
disorder characterized by tonic-clonic seizures which were 
suppressed on phenytoin. His past medical history was re-
markable for the diagnosis of HIV in May 2005. In October 
2006 his CD4 count was 250 cells/cmm and he was started 
on ART (stavudine (d4T), lamivudine (3TC) and nevirap-
ine (NVP)). 
In June 2007, neurological examination showed re-
duced gag reflex, brisk jaw jerk,  positive snout and pal-
momental reflexes. The tongue was atrophic with fas-
ciculations, decreased range of movement and there was 
pseudobulbar speech. The upper limbs showed symmetri-
cal claw like hand deformity with marked wasting and fas-
ciculations of the forearm and hand muscles. Power was 
symmetrically reduced to Medical Research Council grades 
3-4/5 with a proximodistal gradient and more in extensor 
than flexor musculature. The lower limbs were affected 
with marked wasting and slightly reduced power distally. All 
tendon reflexes were pathologically brisk with bilateral ex-
tensor plantar reflexes and Hoffman’s sign. Gait was spastic 
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ABSTRACT
We report an individual with rapidly progressive motor 
neuron disease (MND), phenotypically compatible with 
amyotrophic lateral sclerosis (ALS). The patient described 
in this case report proved positive for human immunodefi-
ciency virus (HIV) and was initiated on antiretroviral ther-
apy (ART). Following ART he clinically stabilised over 10 
years and deteriorated again due to noncompliance or ART 
resistance. HIV infection can give rise to an MND mimic, 
HIV-ALS. The improvement in response to ART supports 
the notion that HIV-ALS is a treatable entity also in Africa. 
This is the first case report of a patient with HIV-ALS and 
long term follow up in Sub-Saharan Africa. The report rais-
es the suggestion that an additional (retro)virus can play a 
role in the aetiology of ALS. 
Introduction 
Patterns of neurological morbidity and mortality in 
low-income countries, like the Sub-Saharan African (SSA) 
country of Tanzania, differ in comparison to high income 
countries, because of a greater burden of communicable 
diseases.1,2 In SSA, the epidemiology and phenotypes of 
non-communicable neurological conditions like neuromus-
cular diseases are likely comparable to other populations 
across the world, although underdiagnosed and -reported.1-3 
While motor neuron disease (MND) has been reported 
from SSA since the nineteen seventies, there have been few 
recent publications.3-7
Human immunodeficiency virus (HIV) infection is 
still one of the leading causes of morbidity and mortality 
in the world and its neurological manifestations are mani-
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with the need for assistance to mobilize. Sensory examina-
tion was normal. (Figure 1)
Full blood count, erythrocyte sedimentation rate (ESR) 
and renal and liver function tests were normal with a nega-
tive VDRL test and a CD4 count of 697 cells/cmm. Chest 
X-ray and CT brain were normal. Cerebrospinal fluid (CSF) 
had normal biochemistry and cell count, and an undetect-
able HIV ribonucleic acid (RNA) viral load. No other cause 
was found for his new onset seizure disorder. There was no 
EMG or MRI facility in Northern Tanzania in 2007/8.
A diagnosis of HIV-ALS was made and his ART regime 
was changed to abacavir (ABC), didanosine (ddl) and lopi-
navir/ritonavir (LPV/r) for better central nervous system 
(CNS) penetration. He developed distal sensory neuropa-
thy and changed ART again in December 2007 (Zidovu-
dine (AZT), 3TC and LPV/r). He was observed with three-
monthly visits, with stable symptoms until January 2008, 
when he was lost to follow-up. 
November 2017, the patient was readmitted to KCMC 
with symptoms of congestive cardiac failure. He was re-
viewed by the same neurologist (WPH) as on his first ad-
mission. After 2008 his symptoms had improved such that 
he could walk and function independently. His swallowing 
had also improved though his speech remained unchanged. 
From two years before the admission in 2017 he required 
assistance when walking. Neurological examination in 2017 
was largely comparable to 2007 apart from slightly more 
pronounced upper motor neuron signs (spasticity) in his 
upper limbs. (Figure 2) 
Over the previous 10-year period the patient said to be 
compliant with his ART.  During the admission in 2017 plas-
ma HIV RNA copies were 7919/ml suggesting lack of ART 
compliance or the emergence of ART resistance. Electro-
myography supported the presence of lower motor neuron 
degeneration in the cranial, cervical, thoracic and lumbosa-
cral segments, based on the Awaji criteria.
Based on the history and physical examination the clin-
ical diagnosis was ‘definite’ ALS. It had stabilised on ART 
for a decade but deteriorated with signs of therapy failure as 
a possible explanation. (Figure 3) 
Discussion 
This is the first case report of a patient in SSA, outside 
South Africa, with HIV-ALS.  The first tentative report of 
Figure 1: photos of the hands from 2008 show wasting of hand muscles and clawing. Photo of the tongue from 2008 showing 
atrophy. 
Figure 2: photos of the hands from 2017 show wasting of hand muscles and clawing. Photo of the tongue from 2017 showing 
atrophy. 
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an association between HIV and MND was of a HIV infect-
ed patient, who developed classic ALS in 1985.16 From 1985 
to 2018 there have been over 30 cases described in case re-
ports and series of HIV-associated MND.10-16 A recent ret-
rospective study from South Africa describes 35 patients 
with HIV-associated motor neuron syndrome compared to 
101 HIV-uninfected MND patients.7
The estimated HIV prevalence rate in adults in Tan-
zania is 4.6%.17 The global incidence of ALS is 1-2 per 
100,000 persons each year with a prevalence of 4-6 cases 
per 100,000.18 The reported MND prevalence rates among 
Black African HIV-infected and HIV-uninfected patients 
are respectively 2.4 and 0.44 cases per 100,000.7,19 HIV was 
suggested to be a causal confounder.7,19
Clinically, HIV-ALS is identical to sALS in HIV-neg-
ative patients but occurs younger, is more severe and pro-
gressive. It can be arrested or (partially) reversed by initia-
tion or optimisation of ART.7,10-15  
In our patient neurological symptoms developed on 
the standard ART regimen despite virological suppression. 
He had started ART when the CD4 count went below 250 
cells/cmm, as was usual at the time. June 2007 he changed 
to ART with good CNS penetration, on which there was no 
progression of symptoms during 8 months. He was lost to 
follow-up for almost 10 years during which he describes a 
long period (7 years) of gradual improvement. From 2015 
there was deterioration in function and on re-evaluation in 
late 2017 he was found to have a high viral load in plasma. 
This suggests treatment failure due to noncompliance or 
ART resistance. Of clinical interest was the nearly identi-
cal pattern of neurological signs over the 10-year period of 
observation.
Partial to full clinical improvement after starting ART 
has also been reported in a number of studies on MND in 
HIV.7,10-15 In a South African study, 17 of 35 patients with 
HIV-associated motor neuron syndrome survived longer 
than 10 years after starting ART.7 Early ART initiation or 
optimisation (≤6 months) and use of ART with CNS pen-
etration improve outcome.7,10,14 
The described patient developed a seizure disor-
der (generalised) around the same time as he started  his 
MND  symptoms, no cause was found.   While the occur-
rence of seizures is increased significantly in patients with 
HIV, they are usually secondary to opportunistic processes 
or vascular in origin, neither of which were present in this 
case. Possibly there is a relation and to reclassify the diag-
nosis to ALS-plus is very reasonable. 
A (retro)viral aetiology in sALS has been hypoth-
esized.19-22 Motor neuron cells are vulnerable to certain vi-
ruses, illustrated by poliomyelitis virus which targets ante-
rior horn cells. HIV can occur in the microglial cells of the 
CNS but is not identified to invade motor neurons. There-
fore the pathophysiology of HIV-ALS might be explained 
by a secondary inflammatory response or an unknown 
opportunistic virus infecting the motor neurons.21 In some 
patients with sALS an increased HERV-K expression has 
been found in cortical neurons and anterior horn cells sug-
gesting that this endogenous retrovirus might play a role in 
the aetiology.10,11,20,22 The serum of this patient could unfor-
tunately not be tested for HERV-K.
Figure 3: timeline. 3TC: lamivudine. ABC: abacavir. ALS: amyotrophic lateral sclerosis. ART: antiretroviral therapy. CD4: 
cluster of differentiation 4. d4T: stavudine. ddI: didanosine. HIV: Human immunodeficiency virus. LPV/r: lopinavir/ritonavir
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Our first report from Tanzania supports the notion that 
HIV-ALS can be a treatable entity also in Africa.7,19 
Teaching points
• HIV infection can give rise to motor neuron dis-
ease including HIV-ALS. 
• HIV should routinely be tested in patients with 
ALS.  
• Antiretroviral therapy can potentially reverse and 
treat HIV-ALS making it a treatable entity, also in 
Africa. 
• Retroviruses might play a role in the aetiology of 
motor neuron disease.
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